PDF(Pubmed)
Abstract：
UNASSIGNED: Cardiac arrhythmias, including ventricular tachycardia (VT), stand as a significant threat to health, often leading to mortality and sudden cardiac death. While conventional treatments for VT exhibit efficacy, cases of refractory VT pose challenges. Stereotactic Arrhythmia Radioablation (STAR) offers a novel approach, delivering precise high-dose radiation to well-defined targets with minimal collateral damage. This study explores the potential of STAR as an alternative therapy, especially for high-risk patients or those with refractory VT.
UNASSIGNED: This research reviews ongoing studies and preliminary investigations into the evaluation of the efficacy and safety of STAR. The method involves targeted radiation delivery, assessing reductions in VT recurrence and the early safety profile in refractory VT patients. However, given STAR\'s early stage and limited clinical evidence, cautious interpretation is advised.
UNASSIGNED: Preliminary findings indicate a reduction in VT recurrence with STAR, suggesting promise as a therapeutic option. Early safety profiles are encouraging, but definitive statements on efficacy and safety require further investigation. Positive initial outcomes underscore the need for additional data and long-term studies.
UNASSIGNED: Stereotactic Arrhythmia Radioablation is recently emerging as a promising treatment for refractory VT. While early results are encouraging, careful interpretation is needed, due to STAR\'s early stages. Ongoing investigations are critical for a comprehensive understanding of its long-term efficacy and tolerability. This review provides fundamental insights into STAR\'s background, principles, pre-treatment procedures, clinical implications, and toxicity, setting the stage for future research in this evolving therapeutic field.
UNASSIGNED: This research reviews ongoing studies and preliminary investigations into the evaluation of the efficacy and safety of STAR. The method involves targeted radiation delivery, assessing reductions in VT recurrence and the early safety profile in refractory VT patients. However, given STAR\'s early stage and limited clinical evidence, cautious interpretation is advised.
UNASSIGNED: Preliminary findings indicate a reduction in VT recurrence with STAR, suggesting promise as a therapeutic option. Early safety profiles are encouraging, but definitive statements on efficacy and safety require further investigation. Positive initial outcomes underscore the need for additional data and long-term studies.
UNASSIGNED: Stereotactic Arrhythmia Radioablation is recently emerging as a promising treatment for refractory VT. While early results are encouraging, careful interpretation is needed, due to STAR\'s early stages. Ongoing investigations are critical for a comprehensive understanding of its long-term efficacy and tolerability. This review provides fundamental insights into STAR\'s background, principles, pre-treatment procedures, clinical implications, and toxicity, setting the stage for future research in this evolving therapeutic field.
摘要：
■心律失常，包括室性心动过速(VT),对健康构成重大威胁，常导致死亡和心源性猝死。虽然室性心动过速的常规治疗方法表现出疗效，难治性VT的病例构成了挑战。立体定向心律失常放射消融（STAR）提供了一种新的方法，以最小的附带损害向明确定义的目标提供精确的高剂量辐射。这项研究探讨了STAR作为替代疗法的潜力，特别是对于高危患者或难治性VT患者。
■本研究回顾了正在进行的研究和对STAR疗效和安全性评估的初步调查。该方法涉及靶向放射递送，评估难治性VT患者VT复发的减少和早期安全性。然而,考虑到STAR的早期阶段和有限的临床证据，建议谨慎解释。
■初步发现表明STAR可减少室性心动过速复发，建议承诺作为一种治疗选择。早期的安全状况令人鼓舞，但关于疗效和安全性的明确陈述需要进一步调查.积极的初步结果强调需要更多的数据和长期研究。
■立体定向心律失常放射性消融术是最近出现的一种治疗难治性室性心动过速的有前景的治疗方法。虽然早期结果令人鼓舞，需要仔细的解释，由于明星的早期阶段。持续的调查对于全面了解其长期疗效和耐受性至关重要。这篇评论提供了对STAR背景的基本见解，原则,预处理程序，临床意义，和毒性，为这个不断发展的治疗领域的未来研究奠定了基础。
■本研究回顾了正在进行的研究和对STAR疗效和安全性评估的初步调查。该方法涉及靶向放射递送，评估难治性VT患者VT复发的减少和早期安全性。然而,考虑到STAR的早期阶段和有限的临床证据，建议谨慎解释。
■初步发现表明STAR可减少室性心动过速复发，建议承诺作为一种治疗选择。早期的安全状况令人鼓舞，但关于疗效和安全性的明确陈述需要进一步调查.积极的初步结果强调需要更多的数据和长期研究。
■立体定向心律失常放射性消融术是最近出现的一种治疗难治性室性心动过速的有前景的治疗方法。虽然早期结果令人鼓舞，需要仔细的解释，由于明星的早期阶段。持续的调查对于全面了解其长期疗效和耐受性至关重要。这篇评论提供了对STAR背景的基本见解，原则,预处理程序，临床意义，和毒性，为这个不断发展的治疗领域的未来研究奠定了基础。
